| Mr Robert Voorhees Jr, | |
|
210 Jupiter Lakes Blvd, Suite 5101, Jupiter, FL 33458-7191 | |
| (561) 741-1876 | |
| (888) 721-1997 |
| Full Name | Mr Robert Voorhees Jr |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 29 Years |
| Location | 210 Jupiter Lakes Blvd, Jupiter, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023040540 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 13616 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Synergy Therapeutics Inc | 0749188498 | 6 |
News Archive
Medical devices implanted in the body for drug delivery, sensing, or tissue regeneration usually come under fire from the host's immune system.
Gene Security Network announced today that they have received a $2 million grant from the National Institutes of Health to conduct a clinical trial applying Parental Support technology for non-invasive prenatal diagnosis.
A new report from the American Cancer Society and other world-leading health groups identifies gaps in research for 20 suspected carcinogens whose potential to cause cancer is as yet unresolved. The report is designed to prioritize agents for additional research, and to lead to well-planned epidemiologic or mechanistic studies leading to more definitive classification of these agents.
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).
› Verified 7 days ago
| Provider Name | Synergy Therapeutics Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1346272853 PECOS PAC ID: 0749188498 Enrollment ID: O20031219000530 |
News Archive
Medical devices implanted in the body for drug delivery, sensing, or tissue regeneration usually come under fire from the host's immune system.
Gene Security Network announced today that they have received a $2 million grant from the National Institutes of Health to conduct a clinical trial applying Parental Support technology for non-invasive prenatal diagnosis.
A new report from the American Cancer Society and other world-leading health groups identifies gaps in research for 20 suspected carcinogens whose potential to cause cancer is as yet unresolved. The report is designed to prioritize agents for additional research, and to lead to well-planned epidemiologic or mechanistic studies leading to more definitive classification of these agents.
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Robert Voorhees Jr, 210 Jupiter Lakes Blvd, Suite 5101, Jupiter, FL 33458-7191 Ph: (561) 741-1876 | Mr Robert Voorhees Jr, 210 Jupiter Lakes Blvd, Suite 5101, Jupiter, FL 33458-7191 Ph: (561) 741-1876 |
News Archive
Medical devices implanted in the body for drug delivery, sensing, or tissue regeneration usually come under fire from the host's immune system.
Gene Security Network announced today that they have received a $2 million grant from the National Institutes of Health to conduct a clinical trial applying Parental Support technology for non-invasive prenatal diagnosis.
A new report from the American Cancer Society and other world-leading health groups identifies gaps in research for 20 suspected carcinogens whose potential to cause cancer is as yet unresolved. The report is designed to prioritize agents for additional research, and to lead to well-planned epidemiologic or mechanistic studies leading to more definitive classification of these agents.
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).
› Verified 7 days ago
Eugene A. Reiff, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 318 Caravelle Dr, Jupiter, FL 33458 Phone: 561-255-6229 Fax: 561-776-8436 | |
Dr. Diana Johnson-ford, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 900 E Indiantown Rd, Suite 111, Jupiter, FL 33477 Phone: 561-288-8810 Fax: 877-464-1813 | |
Kelly Gerlach, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 210 Jupiter Lakes Blvd Ste 5101, Jupiter, FL 33458 Phone: 561-741-1876 Fax: 888-721-1997 | |
Action Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 17380 N Hwy A1a Alt, Suite 305, Jupiter, FL 33477 Phone: 561-741-1661 Fax: 561-741-1663 | |
Ms. Kai N Aird, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 18313 Jupiter Landings Dr, Jupiter, FL 33458 Phone: 561-704-7224 Fax: 561-972-4446 | |
Dr. Eric W. Roberts, PT,DPT,OCS,MTC Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3535 Military Trl, 203, Jupiter, FL 33458 Phone: 561-744-9191 Fax: 561-744-9198 |